CoChat

History of LHRH agonist and combination therapy in prostate cancer

Labrie, F, Belanger, A, Cusan, L, Labrie, C, Simard, J, Luu-The, V, Diamond, P, Gomez, J-L, Candas, B · 1996 · Endocrine Related Cancer
Cited by 46

The DOI matches its Crossref record.

Abstract

An LHRH agonist was first administered to a prostate cancer patient 16 years ago in 1980 while combination therapy with an LHRH agonist and a pure antiandrogen was first administered 14 years ago in 1982. We take this opportunity to review briefly the events which, in our opinion, led to such fundamental changes in the endocrine therapy of prostate cancer. Following the observations of Huggins and his colleagues in 1941, orchiectomy and treatment with high doses of estrogens remained the standard therapy of prostate cancer for 50 years. Discovery of the structure of LHRH in 1971 by Schally and his colleagues stimulated the synthesis of highly potent analogs of LHRH with the objective of treating infertility. However, difficulties were met in finding the proper schedule of administration as well as the dose of LHRH agonists which could maintain stimulatory effects upon repeated administration. In fact, contrary to the expectations of a stimulatory effect, we found in 1977 that treatment of adult male rats with an LHRH agonist for a few days caused some inhibition of ventral prostate and seminal vesicle weight, although the inhibitory effects achieved were small compared with those of castration. It was then believed that the high serum LH levels induced by LHRH agonist treatment caused desensitization of the steroidogenic response in the testes. Even more unexpected was the finding that of all the species studied, man was the most sensitive to the inhibitory action of LHRH agonists on testicular androgen biosynthesis and that medical castration could be easily achieved with LHRH agonists in adult men. In fact, a single intranasal administration of an LHRH agonist to healthy men in 1979 caused the expected acute rise in serum levels of testosterone and its precursors. This increase, however, was followed by a loss of diurnal cyclicity and lowered serum androgen levels which lasted for 3 to 4 days, thus suggesting that man is exquisitely sensitive to the inhibitory action of LHRH agonists. When, in 1980, the first prostate cancer patient received an LHRH agonist at the Laval University Medical Center, it was found that treatment with a high dose of the peptide caused a dramatic reduction in serum testosterone and dihydrotestosterone (DHT) after 2 weeks of administration. Contrary to the usual pattern in medical discoveries, the castration effect of LHRH agonists was first observed in men and not in experimental animals where castration is difficult or sometimes impossible to achieve with daily administration of LHRH agonists. A limitation to the use of LHRH agonists to achieve castration in prostate cancer patients was the temporary rise in serum testosterone and DHT at the start of treatment: such an elevation of serum androgens could cause an exacerbation of the symptoms or flare of prostate cancer. It was then decided to combine a pure antiandrogen with the LHRH agonist. In 1978, we found that the inhibitory effects observed in the rat with the combination of an LHRH agonist associated with a pure antiandrogen were more than additive, especially on seminal vesicle weight. These promising results suggested the use of a pure antiandrogen, not only to avoid the risk of disease flare during the first days of treatment with an LHRH agonist but also to offer the possibility of potentiating the inhibitory effects of the LHRH agonist on androgen-sensitive parameters. Combination therapy with an LHRH agonist and a pure antiandrogen was first administered to a prostate cancer patient in March 1982, also at the Laval University Medical Center. The first patients with advanced prostate cancer treated with combination therapy in a non-randomized study showed a rapid fall in serum prostatic acid phosphatase and a marked improvement of the signs and symptoms of prostate cancer which were highly suggestive of the advantage of combination therapy compared with previous treatments. In fact, the first 58 stage D2 prostate cancer patients showed a positive objective response to combination therapy while a 94% rate of positive response was achieved in the total group of 260 patients entered in this first study. The highly promising results obtained in this initial study provided the stimulus for large-scale randomized and placebo-controlled clinical trials which confirmed the unique benefits of combination therapy on both duration of response and, most importantly, on survival. In fact, combination therapy became the first treatment shown to prolong life in prostate cancer and it has been the gold standard for the endocrine therapy of prostate cancer since 1989. Since localized disease provides the only opportunity for cure of prostate cancer, the same combination therapy was next administered to patients at earlier stages of the disease. Randomized studies performed in patients with localized disease have recently demonstrated that combination therapy administered for 3 months before radical prostatectomy increases th

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1677/erc.0.0030243

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 46

Metadata

Authors
Labrie, F., Belanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V, Diamond, P., Gomez, J.-L., & Candas, B.
Venue
Endocrine Related Cancer
Published
1996-09-01
Volume
3
Issue
3
Pages
243-278
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
OpenAlex
W2017940045
Cited by
46
References
0
FWCI
2.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: History of LHRH agonist and combination therapy in prostate cancer. https://app.cochat.ai/papers/10.1677/erc.0.0030243
The paper
Labrie, F., Belanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V, Diamond, P., Gomez, J.-L., & Candas, B. (1996). History of LHRH agonist and combination therapy in prostate cancer. Endocrine Related Cancer. https://doi.org/10.1677/erc.0.0030243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.